The US Food and Drug Administration is now famously skeptical of applications composed solely of foreign data, especially in oncology, and especially when that data is from China. But two recent review developments suggest that applications with a heavy, but not total reliance, on foreign data could win acceptance.
On March 14, China-based BeiGene, Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?